[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St George's, University of London\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":172},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,38,66,92,127,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100636159","multiplex-immunoassay-quality-assurance-panel-100636159",false,"NCT07562061","mulTiplex Immunoassay qualiTy assuRance Panel","Development of Group B Streptococcus Quality Assurance Panel for the GASTON Multiplex Anti-CPS IgG Immunoassay.","TITRE","Inclusion Criteria:\n\n* HIV-uninfected women who received the GBS6 vaccine during pregnancy and completed the whole period of study participation.\n* Reachable by phone\n* Willing and able to provide consent.\n* Willingness to provide a blood sample.\n\nExclusion Criteria:\n\n* Receipt of blood\u002Fplasma transfusion in the last 3 months\n* Participants who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids.\n* Women who will test positive for Syphilis or HIV at screening\n* Current alcohol abuse or illicit drug use, or with a psychiatric condition\n* Major illness of the mother that, in the investigator's judgment, will substantially increase the risk associated with the participant's participation in the study, including but not limited to the following:\n\nI. heart disease II. severe anaemia (Hemoglobin level less than 7.0g\u002FdL)","FEMALE",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","Collection of serum from women not living with HIV, who received the GBS6 vaccine in the \"a placebo-controlled clinical trial investigating the safety and immunogenicity of GBS6 in pregnant women with and without human immunodeficiency virus (HIV) infection and their infants\" (GBS6) Clinical Trial in Kampala, Uganda, for the Development of Group B Streptococcus quality assurance panel for the GASTON multiplex anti-CPS IgG immunoassay",[24],"Group B Strep Infection","RECRUITING","2026-04-24",{"date":28,"type":29},"2026-05-01","ACTUAL",{"date":31,"type":29},"2026-03-27",{"date":33,"type":20},"2027-01",{"name":35,"class":36},"St George's, University of London","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":45,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100434399","duroplasty-for-injured-cervical-spinal-cord-with-uncontrolled-swelling-100434399","NCT04936620","Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling","DISCUS","Inclusion Criteria:\n\n1. Age ≥16 years\n2. Severe cervical (C2 - T1) traumatic spinal cord injury (AIS grade A-C)\n3. Deemed to require and be suitable for surgery that includes laminectomy by local surgeon\n4. Surgery within 72 hours of traumatic spinal cord injury\n5. Able to provide informed consent or consultee declaration or proxy consent.\n\nExclusion Criteria:\n\n1. Dural tear due to traumatic spinal cord injury\n2. Life-limiting or rehabilitation-restricting co-morbidities\n3. Thoracic or lumbar traumatic spinal cord injury\n4. Other central nervous system disease","ALL","16 Years",{"count":48,"type":20},222,"INTERVENTIONAL",[51],"NA","QUESTION. Does duroplasty improve outcome after spinal cord injury?\n\nWHAT DO WE STUDY? We will investigate whether performing a surgical procedure called duroplasty improves outcomes after spinal cord injury.\n\nWHY SPINAL CORD INJURY? Spinal cord injury is a devastating condition that causes permanent disability such as paralysis, numbness and loss of bladder and bowel control. Currently, there are no treatments shown to improve outcome after spinal cord injury.\n\nWHAT IS DUROPLASTY? Duroplasty is an operation that involves opening the tough membrane around the cord, called the dura, and stitching a patch of artificial dura to expand the space around the swollen cord.\n\nWHY IS DUROPLASTY BEING STUDIED? Based on our preliminary evidence, we think that the dura causes cord pressure after injury. We have shown in a small study of patients that performing this operation safely and effectively reduces pressure on the injured cord.\n\nWHO IS ELIGIBLE? Adult patients with severe spinal cord injuries in the neck who will have surgery within 72 hours.\n\nWHAT TREATMENT? Those who agree to take part will be allocated by chance (like tossing a coin) to standard treatment or standard treatment plus duroplasty. Some patients will also be asked to take part in a smaller study that involves placing probes at the injury site.\n\nWHERE? We will recruit patients from U.K. Major Trauma Centres. Most assessments will be done in U.K. Spinal Injury Centres. Later on, we may recruit from overseas.\n\nHOW LONG? We aim to recruit 222 - 260 patients over 4 years. Patients will be followed up for a year.\n\nWHAT DO WE ASSESS? Patients will be assessed (using questionnaires and by examination) how well they can use their hands, walk, control their bladder and bowel and their quality of life. Some of these assessments will be repeated at 3, 6 and 12 months after surgery.\n\nWHAT IS THE OPTIONAL MECHANISTIC STUDY? DISCUS includes an optional study for at least 50 patients who will take part in the randomised controlled trial. The aim of the mechanistic study is to determine how duroplasty improves outcome, i.e. whether duroplasty reduces cord compression, improves blood flow to the injured cord perfusion, improves cord metabolism and reduces cord inflammation.\n\nWHAT IS THE OPTIONAL INFORMATION STUDY? For the first two years, a study called QuinteT Recruitment Intervention (QRI) is designed to optimise patient recruitment and informed consent in the trauma setting.",[54],"Spinal Cord Injuries",[56],"Decompression, surgical; Neurosurgery; Paralysis","2026-01-26",{"date":59,"type":29},"2026-01-28",{"date":61,"type":29},"2021-10-08",{"date":63,"type":20},"2028-06-30",{"name":35,"class":36},33,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":45,"minAge":73,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":37},"100606300","congenital-and-maternal-point-of-care-rapid-testing-for-syphilis-study-uganda-100606300","NCT07173764","Congenital and Maternal Point of Care Rapid Testing for Syphilis Study, Uganda","COMPARTS","Inclusion Criteria:\n\n* Mothers delivering at Kawempe National Referral Hospital with a positive syphilis rapid diagnostic test during their current pregnancy.\n\nExclusion Criteria:\n\n* Mothers who are unable to give written informed consent.\n* Mothers with evidence of neurological symptoms compatible with neurological syphilis.\n* Mothers who are aged less than 14 years. Emancipated and mature minors are allowed to consent for research per Ugandan law.11\n* Mothers, who in the view of the study team, are unable to adhere to required study procedures","14 Years",{"count":75,"type":20},24,"Syphilis is an infection which affects about 1 in 25 pregnant women in Uganda. If the infection is not diagnosed and treated this can be a risk to the mother and unborn baby's health. This study aims to see whether a new test for syphilis infection in mothers and babies which can give a result in 10 minutes is as good as the standard tests that are done in the laboratory and take hours or days to provide results.",[78,79],"Syphilis","Syphilis, Congenital",[81,82],"syphilis","point of care test","NOT_YET_RECRUITING","2025-09-08",{"date":86,"type":29},"2025-09-15",{"date":88,"type":20},"2025-09",{"date":90,"type":20},"2025-12",{"name":35,"class":36},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":45,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":103,"conditions":104,"keywords":110,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100595707","the-vip3-very-old-intensive-care-patients-study-family-involvement-in-treatment-decisions-for-old-icu-patients-100595707","NCT07035951","The VIP3 (Very Old Intensive Care Patients) Study: Family Involvement in Treatment Decisions for Old ICU Patients","The VIP-3 (Very Old Intensive Care Patients) Study: Decision-making in the Older Intensive Care Unit (ICU) Patient: How Are Family Meetings Implemented Across Diverse Cultures in Europe?","VIP3","Inclusion Criteria:\n\n* Patients admitted to the Intensive Care Unit (ICU) of participating centres\n* Age 75 years and above\n* Expected Length of stay (LOS) \\> 3 days\n\nExclusion Criteria:\n\n* Refusal to participate\n* Limitation of treatment upon ICU arrival (other than Cardiopulmonary Resuscitation-CPR)\n* Planned admission","75 Years",{"count":102,"type":20},2000,"The demographics of the global population is changing with increasing numbers of elderly and co-morbid patients. As a result, more elderly patients will be admitted to the Intensive Care Unit (ICU), which will bring several ethical challenges. It is for this reason the investigators have chosen to focus on this historically neglected and important patient population.\n\nLittle is known about how family meetings are implemented in ICUs in Europe and other parts of the world. However, these meetings contribute to building trust between the family and the ICU team. They are a crucial component for planning and conducting a time limited trials as they provide the opportunity for shared-decision making with the ICU team and with other stakeholders.\n\nThe investigators plan to determine the current practice of communication between ICU staff and patients and their relatives. The investigators expect to find a substantial variation in approaches to family meetings. This information may then help design and further investigate targeted interventions enabling shared decision-making focused on family and patient values.\n\nThe investigators research aim is to to investigate whether Family meetings are used in ICUs across Europe and other regions and, if so, how they are conducted and the influence on patient-centred outcome measures.",[105,106,107,108,109],"Family Members","Critical Illness","Frailty","Communication","Patient Preference",[111,112,113,114,115,116,117,118,119],"Elderly","Critical illness","communication","frailty","family meetings","Intensive care","critical care","shared decision making","patient preference","2025-06-16",{"date":122,"type":29},"2025-06-25",{"date":120,"type":20},{"date":125,"type":20},"2026-12",{"name":35,"class":36},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":45,"minAge":4,"maxAge":134,"enrollmentInfo":135,"targetDuration":137,"studyType":21,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":37},"100505019","observational-study-of-the-management-of-infants-with-congenital-cmv-100505019","NCT05855889","Observational Study of the Management of Infants With Congenital CMV","cCMVnet","Inclusion Criteria: Patients of either sex that have been diagnosed with cCMV infection:\n\n* Through confirmed detection of CMV in urine or saliva, by CMV-DNA PCR (or viral culture \u002F Shell-vial) and\u002For CMV detection in blood or CSF by PCR within the first 21 days of life.\n* Children with cCMV retrospectively diagnosis by positive CMV-DNA PCR in dried blood spots (DBS), collected within 21 days of life.\n* Diagnosed by positive CMV-DNA PCR in dried umbilical cord blood or donated\u002Fstored umbilical cord blood sample\n* Children whose parents give their informed consent to participate in the study\n* Age less than 11 years old\n\nExclusion Criteria:\n\n* Refusal to sign written informed consent of parents\u002F legal guardian.","10 Years",{"count":136,"type":20},200,"6 Years","This is an observational, prospective\u002Fretrospective multicentre, cohort study of children diagnosed with cCMV. This study will contribute to a wider study also recruiting participants in Europe and other countries worldwide. No investigations or treatment will be carried out that are not part of routine clinical practice. Infants with cCMV are routinely followed up from an infectious diseases, audiology, ophthalmology and neurodevelopmental perspective until approximately 6 years of age, or longer if there are ongoing issues. Some children will be retrospectively diagnosed with cCMV in later childhood. Recruitment can be from any centre that manages these patients and has agreed to participate in the study.",[140],"Congenital Cmv","2023-05-19",{"date":143,"type":29},"2023-05-23",{"date":145,"type":29},"2023-03-09",{"date":147,"type":20},"2038-03-30",{"name":35,"class":36},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":45,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":160,"studyType":21,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":37},"100496304","neonatal-infection-surveillance-database-100496304","NCT05742490","Neonatal Infection Surveillance Database","neonIN","Inclusion Criteria:\n\n* Infants on participating Neonatal Units who have an episode of infection with a positive culture\n\nExclusion Criteria:\n\n\\-","1 Minute","12 Months",{"count":159,"type":20},12000,"28 Days","NeonIN is a is a neonatal infection surveillance database which will facilitate active surveillance for bacterial infections through a network of neonatal units, using standardised definitions, proformas and microbiological techniques. The centralised and secure web-based database will allow real-time entry of data and rapid and timely analysis of results.",[163],"Neonatal Infection","2023-02-14",{"date":166,"type":29},"2023-02-24",{"date":168,"type":29},"2013-12-16",{"date":170,"type":20},"2028-11-22",{"name":35,"class":36},""]